IRF4 and diffuse large B-cell lymphoma: Lenalidomide, a drug that alone, or in combination with ibrutinib, can inhibit the growth of ABC-DLBCL cell lines by downregulating transcription factors IRF4 and SPIB, which in turn amplify the NF-κB activity [38], also showed an effect on a several of the MCL cell lines investigated.